Kineta, Inc. [YMTX]

Source: 

Company Overview

Kineta is a leader in the field of innate immunity and is focused on developing potentially differentiated immunotherapies. With KVA12123 in clinical development and the lead anti-CD27 agonist mAb in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.